Immix Biopharma to Present NXC-201 Trial Data From 45 Patients at ASH 2026
Bitget2026/11/04 14:17- Immix Biopharma will present interim NXC-201 trial results at the American Society of Hematology meeting on December 14, 2026.
- The 45-patient NEXICART-2 study evaluates safety and efficacy in the first U.S. CAR-T trial for relapsed or refractory AL amyloidosis.
- The results were selected for an oral presentation scheduled for 11:15 a.m. Central Time in New Orleans.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Pendle Bridge integrates with BungeeExchange, supporting cross-chain transfers across 13 networks
Barclays significantly increased holdings in Tesla (TSLA.US) and Intel (INTC.US) in Q3, and bought Nasdaq ETF options for hedging
According to disclosures by the U.S. Securities and Exchange Commission (SEC), Barclays has submitted its third-quarter holdings report (13F) as of September 30, 2026.
Crypto prices
More
